IRVING, Texas, January 30, 2025--biote Corp. (NASDAQ: BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization ...
Piper Sandler analyst David Westenberg lowered the firm’s price target on Myriad Genetics (MYGN) to $14 from $24 and keeps a Neutral rating on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback